Welcome to STN International! Enter x:x

LOGINID:SSSPTA1208DXJ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS 4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS 5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6	Mar 08	Gene Names now available in BIOSIS
NEWS 7	Mar 22	TOXLIT no longer available
NEWS 8	Mar 22	TRCTHERMO no longer available
NEWS 9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS 10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12	Apr 08	"Ask CAS" for self-help around the clock
NEWS 13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14	Apr 09	ZDB will be removed from STN
NEWS 15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 18	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 19	Jun 03	New e-mail delivery for search results now available
NEWS 20	Jun 10	MEDLINE Reload
NEWS 21	Jun 10	PCTFULL has been reloaded

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:18:11 ON 21 JUN 2002

=> fil reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:18:29 ON 21 JUN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 19 JUN 2002 HIGHEST RN 432491-02-6
DICTIONARY FILE UPDATES: 19 JUN 2002 HIGHEST RN 432491-02-6

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> fil .search

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.38	0.59

FILE 'MEDLINE' ENTERED AT 09:18:47 ON 21 JUN 2002

FILE 'CAPLUS' ENTERED AT 09:18:47 ON 21 JUN 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 09:18:47 ON 21 JUN 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'USPATFULL' ENTERED AT 09:18:47 ON 21 JUN 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 09:18:47 ON 21 JUN 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

```
=> s alpha.sub.v.beta.sub.3
   4 FILES SEARCHED...
L1          488 ALPHA.SUB.V.BETA.SUB.3

=> s l1 and (chelat? or ligand?)
L2          291 L1 AND (CHELAT? OR LIGAND?)

=> s l2 and (target?)
L3          217 L2 AND (TARGET?)

=> s l3 and (metal or metals)
L4          115 L3 AND (METAL OR METALS)

=> s l4 and (peptid?)
L5          110 L4 AND (PEPTID?)

=> s l5 and angiogene?
L6           78 L5 AND ANGIOGENE?
```

```
=> dup rem l6
PROCESSING COMPLETED FOR L6
L7            78 DUP REM L6 (0 DUPLICATES REMOVED)

=> s l6 and (link?)
L8            70 L6 AND (LINK?)

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9            70 DUP REM L8 (0 DUPLICATES REMOVED)

=> d ibib ab 1-
YOU HAVE REQUESTED DATA FROM 70 ANSWERS - CONTINUE? Y/(N):y
```

L9 ANSWER 1 OF 70 USPATFULL
ACCESSION NUMBER: 2002:149165 USPATFULL
TITLE: Cycloalkyl alkanoic acids as integrin receptor antagonists
INVENTOR(S): Khanna, Ish Kumar, Libertyville, IL, UNITED STATES
Clare, Michael, Skokie, IL, UNITED STATES
Gasiecki, Alan F., Vernon Hills, IL, UNITED STATES
Rogers, Thomas, Ballwin, MO, UNITED STATES
Chen, Barbara, Northbrook, IL, UNITED STATES
Russell, Mark, Gurnee, IL, UNITED STATES
Lu, Hwang-Fun, Manchester, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002077321	A1	20020620
APPLICATION INFO.:	US 2001-882186	A1	20010615 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-211781P	20000615 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Pharmacia Corporation, Corporate Patent Dept., 800 N. Lindbergh, Mail Zone 04E, St. Louis, MO, 63167
NUMBER OF CLAIMS: 65
EXEMPLARY CLAIM: 1
LINE COUNT: 3069
AB The present invention relates to a class of compounds represented by the
Formula I ##STR1##

or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .**alpha**..**sub** .**v.beta**..**sub.3** and/or .alpha..sub.V.beta..sub.5 integrin.

L9 ANSWER 2 OF 70 USPATFULL
ACCESSION NUMBER: 2002:141531 USPATFULL
TITLE: Bicyclic alphavbeta3 antagonists
INVENTOR(S): Khanna, Ish Kumar, Libertyville, IL, UNITED STATES
Yu, Yi, Glenview, IL, UNITED STATES
Devadas, Balekudru, Chesterfield, MO, UNITED STATES
Lu, Hwang-Fun, Ballwin, MO, UNITED STATES
Chandrakumar, Nizal S., Vernon Hills, IL, UNITED STATES
Huff, Renee M., Park Ridge, IL, UNITED STATES
Desai, Bipinchandra N., Vernon Hills, IL, UNITED STATES
Nagarajan, Srinivasan Raj, Chesterfield, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002072518	A1	20020613
APPLICATION INFO.:	US 2001-942174	A1	20010829 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-228693P	20000829 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Pharmacia Corpration, Corporate Patent Department, 800 N. Lindbergh Blvd., Main Zone 04E, St. Louis, MO, 63167
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 2625
AB The present invention relates to a class of compounds represented by the
Formula I ##STR1##

or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .**alpha**..**sub** .**v.beta**..**sub.3** and/or .alpha..sub.v.beta..sub.5 integrin.

L9 ANSWER 3 OF 70 USPATFULL
ACCESSION NUMBER: 2002:141514 USPATFULL
TITLE: Hydroxy acid integrin antagonists
INVENTOR(S): Rogers, Thomas, Ballwin, MO, UNITED STATES
Penning, Thomas D., Elmhurst, IL, UNITED STATES
Jiang, Lan, Ballwin, MO, UNITED STATES
Devadas, Balekudru, Chesterfield, MO, UNITED STATES
Ruminiski, Peter, Ballwin, MO, UNITED STATES
VanCamp, Jennifer, Glencoe, MO, UNITED STATES
Yuan, Chester, Thousand, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002072500	A1	20020613
APPLICATION INFO.:	US 2001-963927	A1	20010926 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-235616P	20000927 (60)
	US 2000-241656P	20001019 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Rachel Polster, Pharmacia Corporation Patent Department, Mail Zone 04E, 800 N. Lindbergh, St. Louis, MO, 63167
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 1977
AB The present invention relates to a class of compounds represented by the
Formula I. ##STR1##

or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .**alpha**..**sub** .**v.beta**..**sub.3** and/or the .alpha..sub.v.beta..sub.5 integrin.

L9 ANSWER 4 OF 70 USPATFULL
ACCESSION NUMBER: 2002:140862 USPATFULL
TITLE: **Targeted** therapeutic agents
INVENTOR(S): Li, King Chuen, Bethesda, MD, UNITED STATES
Bednarski, Mark David, Los Altos, CA, UNITED STATES
Wartchow, Charles A., San Francisco, CA, UNITED STATES
Pease, John S., Los Altos, CA, UNITED STATES
DeChene, Neal E., Morgan Hill, CA, UNITED STATES
Trulson, Julie, San Jose, CA, UNITED STATES
Shen, Zhi Min, Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002071843	A1	20020613
APPLICATION INFO.:	US 2001-976254	A1	20011011 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-239684P	20001011 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SWANSON & BRATSCHUN L.L.C., 1745 SHEA CENTER DRIVE, SUITE 330, HIGHLANDS RANCH, CO, 80129
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Page(s)
LINE COUNT: 2866
AB Therapeutic and imaging agents which are comprised of a **targeting** entity, a therapeutic or treatment entity and a **linking** carrier are provided. The **linking** carrier imparts additional advantages to the therapeutic agents, which are not provided by conventional **linking** methods. Preferred agents of the present invention comprise a lipid construct, vesicle, liposome, or polymerized liposome. In some cases, the therapeutic or treatment entity is a radioisotope, chemotherapeutic agent, prodrug, toxin, or gene encoding a protein that exhibits cell toxicity. Preferably, the agent is further comprised of a stabilizing entity that imparts additional advantages to the therapeutic or imaging agent.

L9 ANSWER 5 OF 70 USPATFULL
ACCESSION NUMBER: 2002:133837 USPATFULL
TITLE: **Peptido**-mimetic compounds containing RGD aequence useful as integrin inhibitors
INVENTOR(S): Scolastico, Carlo, Milan, ITALY
Giannini, Giuseppe, Pomezia, ITALY

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002068695	A1	20020606
APPLICATION INFO.:	US 2001-777013	A1	20010206 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-366198, filed on 4 Aug 1999, GRANTED, Pat. No. US 6235877		

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1998-MI2477	19981116

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NIXON & VANDERHYE P.C., 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201-4714
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 2309
AB The present invention discloses compounds of formula (I) ##STR1##

wherein n is the number 0, 1 or 2. There are also disclosed processes for the preparation of said compounds, together with methods for treating pathologies related to an altered .**alpha**..**sub**.**v**.**beta**..**sub**.**3** integrin-mediated cell attachment, in particular wherein the inhibition of **angiogenesis** is desired, for example in tumors, also associated with metastasis.

L9 ANSWER 6 OF 70 USPATFULL
ACCESSION NUMBER: 2002:126754 USPATFULL
TITLE: Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
INVENTOR(S): Peyman, Anuschirwan, Kelkheim, GERMANY, FEDERAL REPUBLIC OF
Will, David William, Schwalbach, GERMANY, FEDERAL REPUBLIC OF
Knolle, Jochen, Kriftel, GERMANY, FEDERAL REPUBLIC OF
Scheunemann, Karlheinz, Liederbach, GERMANY, FEDERAL REPUBLIC OF
Carniato, Denis, Marcoussis, FRANCE
Gourvest, Jean-Francois, Souilly, FRANCE
Gadek, Thomas R., Oakland, CA, UNITED STATES
Mcdowell, Robert, San Francisco, CA, UNITED STATES
Bodary, Sarah Catherine, San Bruno, CA, UNITED STATES
Cuthbertson, Robert Andrew, Victoria, AUSTRALIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002065271	A1	20020530
APPLICATION INFO.:	US 2001-972190	A1	20011009 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-564988, filed on 5 May 2000, PATENTED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-72313P	19980123 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 2261
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Sulfonamide derivatives, their physiologically tolerable salts and their

prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.

L9 ANSWER 7 OF 70 USPATFULL
ACCESSION NUMBER: 2002:119921 USPATFULL
TITLE: Vitronectin receptor antagonist pharmaceuticals
INVENTOR(S): Harris, Thomas D., Salem, NH, UNITED STATES
Rajopadhye, Milind, Westford, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002061909	A1	20020523
APPLICATION INFO.:	US 2001-948390	A1	20010907 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-465300, filed on 17 Dec 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-112732P	19981218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DuPont Pharmaceuticals Company, c/o E. I. duPont de Nemours and Company, Legal - Patents, 1007 Market Street, Wilmington, DE, 19898
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
LINE COUNT: 7403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes novel compounds of the formula:

(Q).sub.d--L.sub.n--C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L9 ANSWER 8 OF 70 USPATFULL
ACCESSION NUMBER: 2002:85600 USPATFULL
TITLE: Lactone integrin antagonists
INVENTOR(S): Ruminski, Peter, Ballwin, MO, UNITED STATES
Penning, Thomas D., Elmhurst, IL, UNITED STATES
Jiang, Lan, Ballwin, MO, UNITED STATES
Devadas, Balekudru, Chesterfield, MO, UNITED STATES
Rogers, Thomas, Ballwin, MO, UNITED STATES
VanCamp, Jennifer, Glencoe, MO, UNITED STATES
Yuan, Chester, Thousand, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002045645	A1	20020418
APPLICATION INFO.:	US 2001-963926	A1	20010926 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-241633P	20001019 (60)
	US 2000-235617P	20000927 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Rachel A. Polster, Pharmacia Corporation Patent Department, Mail Zone 04E, 800 N. Lindbergh, St. Louis, MO, 63167
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 2059
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a class of compounds represented by the

Formula I. ##STR1##

or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .**alpha**..**sub**.**v**.**beta**..**sub**.**3** and/or the .alpha..sub.v.beta..sub.5 integrin.

L9 ANSWER 9 OF 70 USPATFULL
ACCESSION NUMBER: 2002:78225 USPATFULL
TITLE: Vitronectin receptor antagonist pharmaceuticals
INVENTOR(S): Harris, Thomas D., Salem, NH, UNITED STATES
Rajopadhye, Milind, Westford, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002041878	A1	20020411
APPLICATION INFO.:	US 2001-948807	A1	20010907 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-465300, filed on 17 Dec 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-112732P	19981218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Peter L. Dolan, DuPont Pharmaceuticals Company, c/o E. I. duPont de Nemours and Company, 1007 Market Street, Wilmington, DE, 19898
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
LINE COUNT: 7398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes novel compounds of the formula:

(Q).sub.d-L.sub.n-C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L9 ANSWER 10 OF 70 USPATFULL
ACCESSION NUMBER: 2002:72996 USPATFULL
TITLE: Vitronectin receptor antagonist
INVENTOR(S): Heerding, Dirk, Malvern, PA, UNITED STATES
PATENT ASSIGNEE(S): SmithKline Beecham Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002040136	A1	20020404
APPLICATION INFO.:	US 2001-996141	A1	20011128 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-800057, filed on 5 Mar 2001, PENDING Continuation of Ser. No. US 2000-509142, filed on 22 Mar 2000, ABANDONED A 371 of International Ser. No. WO 1998-US19949, filed on 24 Sep 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-59832P	19970924 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, Corporate Intellectual Property - UW2220, P.O. Box 1539, King of Prussia, PA, 19406-0939
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 1449
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula (I) is disclosed which is a vitronectin receptor antagonist and is useful in the treatment of osteoporosis: ##STR1##

or a pharmaceutically acceptable salt thereof.

L9 ANSWER 11 OF 70 USPATFULL
ACCESSION NUMBER: 2002:43683 USPATFULL
TITLE: 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
INVENTOR(S): Boschelli, Diane Harris, New City, NY, UNITED STATES
Wang, Yanong, Nanuet, NY, UNITED STATES
Boschelli, Frank Charles, New City, NY, UNITED STATES
Berger, Dan Maarten, New City, NY, UNITED STATES
Zhang, Nan, Bayside, NY, UNITED STATES
Powell, Dennis William, Cortlandt Manor, NY, UNITED STATES
Ye, Fei, Nanuet, NY, UNITED STATES
Yamashita, Ayako, Englewood, NJ, UNITED STATES
Demorin, Frenel Fils, Thousand Oaks, CA, UNITED STATES
Wu, Biqi, Nanuet, NY, UNITED STATES
Tsou, Hwei-Ru, New City, NY, UNITED STATES
Overbeek-Klumpers, Elsebe Geraldine, Bk Bergentheim, NETHERLANDS
Wissner, Allan, Ardsley, NY, UNITED STATES
PATENT ASSIGNEE(S): American Home Products Corporation, Madison, NJ, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002026052	A1	20020228
APPLICATION INFO.:	US 2001-820070	A1	20010328 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-219322P	20000328 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Egon E. Berg, American Home Products Corporation, Patent Law Department, Five Giralda Farms, Madison, NJ, 07940
NUMBER OF CLAIMS: 145
EXEMPLARY CLAIM: 1
LINE COUNT: 15941
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides compounds of Formula (I), having the structure ##STR1##

where T, Z, X, A, R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, R.sup.4, and n are defined herein, or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of osteoporosis and polycystic kidney disease.

L9 ANSWER 12 OF 70 USPATFULL
ACCESSION NUMBER: 2002:32565 USPATFULL
TITLE: Vitronectin receptor antagonist
INVENTOR(S): Bondinell, William E., Wayne, PA, UNITED STATES
PATENT ASSIGNEE(S): SmithKline Beecham Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019387	A1	20020214
APPLICATION INFO.:	US 2001-956682	A1	20010920 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-509184, filed on 21 Mar 2000, PENDING A 371 of International Ser. No. WO 1998-US19987, filed on 24 Sep 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-59867P	19970924 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, Corporate Intellectual Property - UW2220, P.O. Box 1539, King of Prussia, PA, 19406-0939
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 1237
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula (I) is disclosed which is a vitronectin receptor antagonist and is useful in the treatment of osteoporosis: ##STR1##

or a pharmaceutically acceptable salt thereof.

L9 ANSWER 13 OF 70 USPATFULL
ACCESSION NUMBER: 2002:26835 USPATFULL
TITLE: QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS
INVENTOR(S): HARRIS, THOMAS DAVID, SALEM, NH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002015680	A1	20020207
APPLICATION INFO.:	US 1999-281209	A1	19990330 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-80150P	19980331 (60)
	US 1998-112715P	19981218 (60)
	US 1998-112829P	19981218 (60)
	US 1998-112732P	19981218 (60)
	US 1998-112831P	19981218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Dupont Pharmaceuticals Company, Legal Department - Patents, 1007 Market Street, Wilmington, DE, 19898
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
LINE COUNT: 6696
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes novel compounds of the formula:

(Q).sub.d--L.sub.n--C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L9 ANSWER 14 OF 70 USPATFULL
ACCESSION NUMBER: 2002:3593 USPATFULL
TITLE: PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS
INVENTOR(S): RAJOPADHYE, MILIND, WESTFORD, MA, UNITED STATES
EDWARDS, D. SCOTT, BURLINGTON, MA, UNITED STATES
HARRIS, THOMAS D., SAMEL, NH, UNITED STATES
HAMINWAY, STUART J., LOWELL, MA, UNITED STATES
LIU, SHUANG, CHELMSFORD, MA, UNITED STATES
SINGH, PRAHLAD R., ARLINGTON, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002001566	A1	20020103
APPLICATION INFO.:	US 1999-281474	A1	19990330 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-80150P	19980331 (60)
	US 1998-112715P	19981218 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DAVID H. VANCE, DUPONT PHARMACEUTICALS COMPANY, C/O E. I. DU PONT DE NEMOURS AND CO., LEGAL - PATENTS-1007 MARKET STREET, WILMINGTON, DE, 19898
NUMBER OF CLAIMS: 51
EXEMPLARY CLAIM: 1
LINE COUNT: 5872
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes novel compounds of the formula:

(Q).sub.d--L.sub.n--C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L9 ANSWER 15 OF 70 USPATFULL
ACCESSION NUMBER: 2002:143940 USPATFULL
TITLE: Cancer treatment methods using antibodies to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Ran, Sophia, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6406693	B1	20020618
APPLICATION INFO.:	US 1999-351543		19990712 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-110608P	19981202 (60)
	US 1998-92672P	19980713 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Williams, Morgan and Amerson
NUMBER OF CLAIMS: 63
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 7541
AB Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.

L9 ANSWER 16 OF 70 USPATFULL
ACCESSION NUMBER: 2002:136772 USPATFULL
TITLE: Affinity labeling libraries with tagged leaving group
INVENTOR(S): Krantz, Alexander, Menlo Park, CA, United States
Hanel, Arthur M., San Francisco, CA, United States
Huang, Wolin, Foster City, CA, United States
PATENT ASSIGNEE(S): ConjuChem, Inc., Montreal, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6403324	B1	20020611
APPLICATION INFO.:	US 1998-42234		19980313 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-714754, filed on 16 Sep 1996, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Ponnaluri, Padmashri
LEGAL REPRESENTATIVE: Morrison & Foerster LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 940
AB Methods and compositions are provided for identifying compounds having affinity to a **target** site. The method provides for the affinity group to be a leaving group from a reactive functionality capable of forming a covalent bond to the **target** site. One can combine the compound comprising the **target** site with the library, and assay for the resulting composition of the leaving groups. The leaving groups having the highest concentration can be identified as the groups having the binding highest affinity for the **target** site. The selected compounds may then be used for labeling the **target** molecule, particularly where the **target** molecule is naturally found in a complex mixture, such as a physiological fluid, like blood. By affinity labeling in vivo, the lifetime of physiologically active entities can be greatly enhanced by becoming bound to long lived blood components. The covalently bound entity may also serve as an antagonist or agonist of a particular binding proteins or as an enzyme inhibitor.

L9 ANSWER 17 OF 70 USPATFULL
ACCESSION NUMBER: 2002:129978 USPATFULL
TITLE: Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
INVENTOR(S): Wehner, Volkmar, Sandberg, GERMANY, FEDERAL REPUBLIC OF
Knolle, Jochen, Kriftel, GERMANY, FEDERAL REPUBLIC OF
Stilz, Hans Ulrich, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Gourvest, Jean-Francois, Biberonne, FRANCE
Carniato, Denis, Clamart, FRANCE
Gadek, Thomas Richard, Oakland, CA, United States
McDowell, Robert, San Francisco, CA, United States
Pitti, Robert Maurice, El Cerrito, CA, United States
Bodary, Sarah Catherine, San Bruno, CA, United States
PATENT ASSIGNEE(S): Aventis Pharma S.A., Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6399620	B1	20020604
APPLICATION INFO.:	US 2000-606080		20000629 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-899503, filed on 24 Jul 1997, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19629816	19960724

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Coleman, Brenda
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There are described cycloalkyl derivatives of the formula (I)

R.sup.1--Y--A--B--D--E--F--G (I)

in which R.sup.1, Y, A, B, D, E, F and G have the meaning indicated herein, their preparation and their use as medicaments. The compounds according to the invention can be used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 18 OF 70 USPATFULL
ACCESSION NUMBER: 2002:116292 USPATFULL
TITLE: Iminoguanidine derivatives, preparation method, use as medicines
INVENTOR(S): Carniato, Denis, Cagnes sur Mer, FRANCE
Gourvest, Jean-Francois, Claye-Souilly, FRANCE
Ruxer, Jean-Marie, Issy les Moulineaux, FRANCE
Knolle, Jochen, Kriftel, GERMANY, FEDERAL REPUBLIC OF
Peyman, Anurschirwan, Kelkheim, GERMANY, FEDERAL REPUBLIC OF
Bodary, Sarah C., San Bruno, CA, United States
Gadek, Thomas R., Oakland, CA, United States
PATENT ASSIGNEE(S): Aventis Pharma S.A., FRANCE (non-U.S. corporation)
Genentech, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6391904	B1	20020521
	WO 2000031044		20000602
APPLICATION INFO.:	US 2001-856693		20010629 (9)
	WO 1999-FR2880		19991123
			20010629 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1998-14780	19981124

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Stockton, Laura L.
LEGAL REPRESENTATIVE: Bierman, Muserlian and Lucas
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1528
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula ##STR1##

where the substituents are defined in the specification and its pharmaceutically acceptable salts and prodrugs thereof useful as antagonists of vitronectin receptors.

L9 ANSWER 19 OF 70 USPATFULL
ACCESSION NUMBER: 2002:109033 USPATFULL
TITLE: Vitronectin receptor antagonists, their preparation and
their use
INVENTOR(S): Wehner, Volkmar, Sandberg, GERMANY, FEDERAL REPUBLIC OF
Stilz, Hans Ulrich, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Peyman, Anuschirwan, Kelkheim, GERMANY, FEDERAL REPUBLIC OF
Knolle, Jochen, Kriftel, GERMANY, FEDERAL REPUBLIC OF
Ruxer, Jean-Marie, Issy les Moulineaux, FRANCE
Carniato, Denis, Marcoussis, FRANCE
Lefrancois, Jean-Michel, Livry Gargan, FRANCE
Gadek, Thomas Richard, Oakland, CA, United States
McDowell, Robert, San Francisco, CA, United States
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, GERMANY,
FEDERAL REPUBLIC OF (non-U.S. corporation)
Genentech, Inc., San Francisco, CA, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6387895	B1	20020514
APPLICATION INFO.:	US 2001-777011		20010206 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-412331, filed on 5 Oct 1999, now patented, Pat. No. US 6207663 Division of Ser. No. US 1997-995521, filed on 22 Dec 1997, now patented, Pat. No. US 6011045		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19653647	19961220

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3251
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of the formula I

A--B--D--E--F--G (I)

in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 20 OF 70 USPATFULL
ACCESSION NUMBER: 2002:81463 USPATFULL
TITLE: .alpha..nu..beta.3 integrin antagonists in combination with chemotherapeutic agents
INVENTOR(S): Cunningham, Jay, 3733 N. Bell Ave., Chicago, IL, United
States 60618
Gordon, Gary B., 3282 University Ave., Highland Park, IL, United States 60035
Nickols, G. Allen, 2690 Lenee La., Wentzville, MO, United States 63385
Westlin, William F., 15989 Woodlet Park Ct., Chesterfield, MO, United States 63017
Rogers, Thomas Edward, 755 Trago Creek Dr., Ballwin, MO, United States 63021
Ruminski, Peter Gerrard, 7687 Pierside Dr., Dardenne Prairie, MO, United States 63366

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6372719	B1	20020416
APPLICATION INFO.:	US 1999-262725		19990304 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-34270, filed on 4 Mar 1998, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Goldberg, Jerome D.
LEGAL REPRESENTATIVE: Scrivner, Alan, Polster, Rachel
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2306
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds of the formula ##STR1##

and pharmaceutically acceptable salts and isomers thereof administered in combination with chemotherapeutic agents.

L9 ANSWER 21 OF 70 USPATFULL
ACCESSION NUMBER: 2002:75564 USPATFULL
TITLE: Integrin-**linked** kinase and its uses
INVENTOR(S): Dedhar, Shoukat, Vancouver, CANADA
Hannigan, Greg, Ontario, CANADA
PATENT ASSIGNEE(S): Sunnybrook Health Science Centre, Toronto, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6369205	B1	20020409
APPLICATION INFO.:	US 2000-566906		20000509 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-390425, filed on 3 Sep 1999 Continuation-in-part of Ser. No. US 1997-955841, filed on 21 Oct 1997, now patented, Pat. No. US 6013782
Continuation-in-part of Ser. No. US 1996-752345, filed on 19 Nov 1996, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-9074P	19951221 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Clark, Deborah J. R.
ASSISTANT EXAMINER: Chen, Shin-Lin
LEGAL REPRESENTATIVE: Sherwood, Pamela J., Bozicevic, Field & Francis LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 3200
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for isolating ILK genes are provided, The ILK nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.

L9 ANSWER 22 OF 70 USPATFULL
ACCESSION NUMBER: 2002:70095 USPATFULL
TITLE: Methods and compositions for inhibiting inflammation and **angiogenesis** comprising a mammalian CD97 .alpha. subunit
INVENTOR(S): Kelly, Kathleen, North Potomac, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6365712	B1	20020402
	WO 9817796		19980430
APPLICATION INFO.:	US 1999-284819		19990820 (9)
	WO 1997-US19772		19971024
			19990820 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-27871P	19961025 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Huff, Sheela
ASSISTANT EXAMINER: Harris, Alana M.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 3805
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated proteins comprising the T-cell surface antigen CD97 .alpha. are provided. Compositions and methods for making and detecting CD97 .alpha. are also provided. Further, the invention provides diagnostic and therapeutic methods and compositions for medical conditions involving CD97.

L9 ANSWER 23 OF 70 USPATFULL
ACCESSION NUMBER: 2002:19060 USPATFULL
TITLE: Antibody conjugate compositions for selectively inhibiting VEGF
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Brekken, Rolf A., Seattle, WA, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6342221	B1	20020129
APPLICATION INFO.:	US 2000-561108		20000428 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131432P	19990428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Huynh, Phuong N.
LEGAL REPRESENTATIVE: Williams, Morgan and Amerson
NUMBER OF CLAIMS: 68
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 10492
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit **angiogenesis** and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

L9 ANSWER 24 OF 70 USPATFULL
ACCESSION NUMBER: 2002:19058 USPATFULL
TITLE: Antibody compositions for selectively inhibiting VEGF
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Brekken, Rolf A., Seattle, WA, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6342219	B1	20020129
APPLICATION INFO.:	US 2000-561500		20000428 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131432P	19990428 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Chan, Christina Y.
ASSISTANT EXAMINER: Huynh, Phuong N.
LEGAL REPRESENTATIVE: Williams, Morgan and Amerson
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 20
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 10403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit **angiogenesis** and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

L9 ANSWER 25 OF 70 USPATFULL
ACCESSION NUMBER: 2002:13996 USPATFULL
TITLE: Guanidine derivatives as inhibitors of cell adhesion
INVENTOR(S): Peyman, Anuschirwan, Kelkheim, GERMANY, FEDERAL REPUBLIC OF
Knolle, Jochen, San Francisco, CA, United States
Scheunemann, Karl-Heinz, Liederbach, GERMANY, FEDERAL REPUBLIC OF
Will, David William, Kriftel, GERMANY, FEDERAL REPUBLIC
OF
Carniato, Denis, Marcoussis, FRANCE
Gourvest, Jean-Francois, Claye Souilly, FRANCE
Gadek, Thomas R., Oakland, CA, United States
Bodary, Sarah Catherine, San Bruno, CA, United States
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6340679	B1	20020122
APPLICATION INFO.:	US 2000-502577		20000211 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-102916	19990213

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Rao, Deepak
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1625
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to acylguanidine derivatives of the formula I ##STR1##

in which R.sup.1, R.sup.2, R.sup.4, Ar, X and n have the meanings indicated in the claims, their physiologically tolerable salts and their

prodrugs. The compounds of the formula I are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion. They inhibit, for example, bone resorption by osteoclasts and are suitable for the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example osteoporosis. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceutical preparations, and pharmaceutical preparations comprising them.

L9 ANSWER 26 OF 70 USPATFULL
ACCESSION NUMBER: 2002:9751 USPATFULL
TITLE: Integrin-linked kinase and its uses
INVENTOR(S): Dedhar, Shoukat, Vancouver, CANADA
Hannigan, Greg, Ontario, CANADA
PATENT ASSIGNEE(S): Sunnybrook Health Science Centre, Toronto, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6338958	B1	20020115
APPLICATION INFO.:	US 1999-390425		19990903 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-35706, filed on 5 Mar 1998, now patented, Pat. No. US 6001622 Continuation-in-part of Ser. No. US 1997-955841, filed on 21 Oct 1997, now patented, Pat. No. US 6013782 Continuation-in-part of Ser. No. US 1996-752345, filed on 19 Nov 1996, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-9074P	19951221 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Clark, Deborah J. R.
ASSISTANT EXAMINER: Chen, Shin-Lin
LEGAL REPRESENTATIVE: Sherwood, Pamela J., Bozicevic, Field & Francis LLP
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 3203
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for isolating ILK genes are provided. The ILK nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that

modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such

as identification of cell type based on expression, and the like.

L9 ANSWER 27 OF 70 USPATFULL
ACCESSION NUMBER: 2001:194406 USPATFULL
TITLE: Osteopontin-derived chemotactic and inhibitory agents and uses therefor
INVENTOR(S): Ashkar, Samy, Boston, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001036921	A1	20011101
APPLICATION INFO.:	US 2000-729873	A1	20001205 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2000-US10344	20000417
	US 1999-129764P	19990415 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
LINE COUNT: 1763
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel osteopontin-derived chemotactic and inhibitory agents are described. Methods of using these agents are also described.

L9 ANSWER 28 OF 70 USPATFULL
ACCESSION NUMBER: 2001:155774 USPATFULL
TITLE: Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors
INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of
Knolle, Jochen, Kriftel, Germany, Federal Republic of
Stilz, Hans Ulrich, Frankfurt, Germany, Federal Republic of
Carniato, Denis, Marcoussis, France
Gourvest, Jean-Francois, Clay Souilly, France
Gadek, Tom, Oakland, CA, United States
McDowell, Robert, San Francisco, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001021708	A1	20010913
APPLICATION INFO.:	US 2001-798995	A1	20010306 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-821253, filed on 20 Mar 1997, GRANTED, Pat. No. US 6218415		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19610919	19960320
	DE 1996-19626701	19960703
	DE 1996-19635522	19960902

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Michele M. Simkin, FOLEY & LARDNER, Suite 500, 3000 K Street, N.W., Washington, DC, 20007-5109
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 3304
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to 5-membered ring heterocycles of the formula I, ##STR1##

in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation and to their use as medicaments.

The novel compounds are used as vitronectin receptor antagonists and as inhibitors of bone reabsorption.

L9 ANSWER 29 OF 70 USPATFULL
ACCESSION NUMBER: 2001:123579 USPATFULL
TITLE: Vitronectin receptor antagonists, their preparation and their use
INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of
Stilz, Hans Ulrich, Frankfurt, Germany, Federal Republic of
Peyman, Anuschirwan, Kelkheim, Germany, Federal Republic of
Scheunemann, Karlheinz, Liederbach, Germany, Federal Republic of
Ruxer, Jean-Marie, Issy les Moulineaux, France
Carniato, Denis, Marcoussis, France
Lefrancois, Jean-Michel, Livry Gargan, France
Gadek, Thomas Richard, Oakland, CA, United States
McDowell, Robert, San Francisco, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001011087	A1	20010802
APPLICATION INFO.:	US 2001-778755	A1	20010208 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-412314, filed on 5 Oct 1999, GRANTED, Pat. No. US 6218387 Division of Ser. No. US 1997-995522, filed on 22 Dec 1997, GRANTED, Pat. No. US 5990145

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19653645	19961220

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Michele M. Simkin, FOLEY & LARDNER, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, DC, 20007-5109
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 2527
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Vitronectin receptor antagonists, their preparation and their use The present invention relates to compounds of the formula 1,

A--B--D--E--F--G (I)

in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 30 OF 70 USPATFULL
ACCESSION NUMBER: 2001:231041 USPATFULL
TITLE: **Targeted** diagnostic/therapeutic agents having more than one different vectors
INVENTOR(S): Klaveness, Jo, Oslo, Norway
Rongved, P.ang.l, Oslo, Norway
H.o slashed.gset, Anders, Oslo, Norway
Tolleshaug, Helge, Oslo, Norway
Cuthbertson, Alan, Oslo, Norway
Hoff, Lars, Oslo, Norway
Bryn, Klaus, Oslo, Norway
Hellebust, Halldis, Oslo, Norway
Solbakken, Magne, Oslo, Norway
PATENT ASSIGNEE(S): Nycomed Imaging AS, Oslo, Norway (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6331289	B1	20011218
APPLICATION INFO.:	US 1997-959206		19971028 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22369	19961028
	GB 1997-2195	19970204
	GB 1997-8265	19970424
	GB 1997-11837	19970606
	GB 1997-11839	19970606
	US 1997-49263P	19970606 (60)
	US 1997-49266P	19970607 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Hartley, Michael G.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 4091
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Targetable** diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a **target**.

L9 ANSWER 31 OF 70 USPATFULL
ACCESSION NUMBER: 2001:231038 USPATFULL
TITLE: Structurally determined cyclic metallo-constructs and applications
INVENTOR(S): Sharma, Shubh D., Plainsboro, NJ, United States
PATENT ASSIGNEE(S): Palatin Technologies, Inc., Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6331285	B1	20011218
APPLICATION INFO.:	US 1999-464358		19991215 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-660697, filed on 5 Jun 1996, now patented, Pat. No. US 6027711
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jones, Dameron L.
LEGAL REPRESENTATIVE: Slusher, Stephen A.Peacock, Myers & Adams
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 4839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A metallo-construct, which may be a **peptide**, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a **metal** ion. The **peptide** constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing **metal** ions, so that substantially all of the valences of the **metal** ion are satisfied upon complexation of the **metal** ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the **metal** ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a **ligand** or mimic a known biological-function domain. The construct has substantially higher affinity for its **target** upon labeling with a **metal** ion.

L9 ANSWER 32 OF 70 USPATFULL
ACCESSION NUMBER: 2001:214639 USPATFULL
TITLE: Indazole vitronectin receptor antagonist pharmaceuticals
INVENTOR(S): Rajopadhye, Milind, Westford, MA, United States
Harris, Thomas David, Salem, NH, United States
PATENT ASSIGNEE(S): DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6322770	B1	20011127
APPLICATION INFO.:	US 1999-281207		19990330 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jones, Dameron L.
LEGAL REPRESENTATIVE: Dolan, Peter L.
NUMBER OF CLAIMS: 70
EXEMPLARY CLAIM: 1
LINE COUNT: 6228
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention d ribs novel compounds of the formula:

(Q).sub.d --L.sub.n --C.sub.h,

useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

L9 ANSWER 33 OF 70 USPATFULL
ACCESSION NUMBER: 2001:197016 USPATFULL
TITLE: Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
INVENTOR(S): Peyman, Anuschirwan, Kelkheim, Germany, Federal Republic of
Will, David William, Schwalbach, Germany, Federal Republic of
Knolle, Jochen, Kriftel, Germany, Federal Republic of
Scheunemann, Karlheinz, Liederbach, Germany, Federal Republic of
Carniato, Denis, Marcoussis, France
Gourvest, Jean-Francois, Souilly, France
Gadek, Thomas R., Oakland, CA, United States
McDowell, Robert, San Francisco, CA, United States
Bodary, Sarah Catherine, San Bruno, CA, United States
Cuthbertson, Robert Andrew, Victoria, Australia
PATENT ASSIGNEE(S): Adventis Pharma Deutschland GmbH, Frankfurt, Germany, Federal Republic of (non-U.S. corporation)
Genentech, Inc., South San Francisco, CA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6313119	B1	20011106
APPLICATION INFO.:	US 2000-564988		20000505 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-235271, filed on 22 Jan 1999, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-72313P	19980123 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 2237
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Sulfonamide derivatives, their physiologically tolerable salts and their
prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.

L9 ANSWER 34 OF 70 USPATFULL
ACCESSION NUMBER: 2001:196603 USPATFULL
TITLE: Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Ran, Sophia, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6312694	B1	20011106
APPLICATION INFO.:	US 1999-351457		19990712 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92589P	19980713 (60)
	US 1998-110600P	19981202 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Williams, Morgan & Amerson
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1,2,3,4
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 8243
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolaminie, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-**targeted** diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.

L9 ANSWER 35 OF 70 USPATFULL
ACCESSION NUMBER: 2001:179101 USPATFULL
TITLE: Isoxazoline fibrinogen receptor antagonists
INVENTOR(S): Smallheer, Joanne M., Landenberg, PA, United States
Wang, Shuaige, West Chester, PA, United States
Jadhav, Prabhakar Kondaji, Wilmington, DE, United States
PATENT ASSIGNEE(S): DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6303609	B1	20011016
APPLICATION INFO.:	US 1999-442682		19991118 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-108835P	19981118 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Patel, Sudhaker B.
LEGAL REPRESENTATIVE: Larsen, Scott K., Belfield, Jing S.
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
LINE COUNT: 6537
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel isoxazolines and isoxazoles of formula (I): ##STR1##

or a pharmaceutically acceptable salt or prodrug form thereof. The invention relates to novel isoxazolines which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone
or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

L9 ANSWER 36 OF 70 USPATFULL
ACCESSION NUMBER: 2001:131335 USPATFULL
TITLE: Thiophene integrin inhibitors
INVENTOR(S): Labrecque, Denis, Laval, Canada
Attardo, Giorgio, Laval, Canada
Bubenik, Monica, Montreal, Canada
Chan, Laval, Kirkland, Canada
Charron, Sylvie, Montreal, Canada
Denis, Real, Laval, Canada
Falardeau, Guy, Laval, Canada
Lamothe, Serge, Boisbriand, Canada
Preville, Patrice, Blainville, Canada
Zacharie, Boulos, Laval, Canada
PATENT ASSIGNEE(S): BioChem Pharma Inc., Laval, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6274620	B1	20010814
APPLICATION INFO.:	US 2000-588574		20000607 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-137726P	19990607 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Lambkin, Deborah C.
LEGAL REPRESENTATIVE: Arent Fox Kintner Plotkin & Kahn PLLC
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
LINE COUNT: 2618
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention comprises compounds that are effective inhibitors of integrins, particularly .alpha.v.beta.3 and .alpha.v.beta.5 integrins. Particularly, the compounds are of formula I ##STR1##

and pharmaceutically acceptable salts thereof wherein X,Y.sub.1 W, R1 to
R5, A and B are defined according to the disclosure herein.

L9 ANSWER 37 OF 70 USPATFULL
ACCESSION NUMBER: 2001:116526 USPATFULL
TITLE: **Targeted** ultrasound contrast agents
INVENTOR(S): Klaveness, Jo, Oslo, Norway
Rongved, P.ang.l, Oslo, Norway
L.o slashed.vhaug, Dagfinn, Oslo, Norway
PATENT ASSIGNEE(S): Nycomed Imaging AS, Oslo, Norway (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6264917	B1	20010724
APPLICATION INFO.:	US 1997-958993		19971028 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22367	19961028
	GB 1996-22368	19961028
	GB 1997-699	19970115
	GB 1997-8265	19970424
	GB 1997-11842	19970606
	GB 1997-11846	19970606
	US 1997-49264P	19970607 (60)
	US 1997-49268P	19970607 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Hartley, Michael G.
LEGAL REPRESENTATIVE: Bacon & Thomas
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 5477
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Targetable** diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilised by monolayers of film-forming surfactants, the reporter being coupled or **linked** to at least one vector.

L9 ANSWER 38 OF 70 USPATFULL
ACCESSION NUMBER: 2001:111808 USPATFULL
TITLE: Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
INVENTOR(S): Klaveness, Jo, Oslo, Norway
Rongved, P.ang.l, Oslo, Norway
H.o slashed.gset, Anders, Oslo, Norway
Tolleshaug, Helge, Oslo, Norway
N.ae butted.vestad, Anne, Oslo, Norway
Hellebust, Halldis, Oslo, Norway
Hoff, Lars, Oslo, Norway
Cuthbertson, Alan, Oslo, Norway
L.o slashed.vhaug, Dagfinn, Oslo, Norway
Solbakken, Magne, Oslo, Norway
PATENT ASSIGNEE(S): Nycomed Imaging AS, Oslo, Norway (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6261537	B1	20010717
APPLICATION INFO.:	US 1997-960054		19971029 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-958993, filed on 28 Oct 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22367	19961028
	GB 1996-22368	19961028
	GB 1997-699	19970115
	GB 1997-8265	19970424
	GB 1997-11842	19970606
	GB 1997-11846	19970606
	US 1997-49264P	19970607 (60)
	US 1997-49265P	19970607 (60)
	US 1997-49268P	19970607 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Hartley, Michael G.
LEGAL REPRESENTATIVE: Bacon & Thomas, Fichter, Richard E.
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 5614
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Targetable** diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilised by monolayers of film-forming surfactants, the reporter being coupled or **linked** to at least one vector.

L9 ANSWER 39 OF 70 USPATFULL
ACCESSION NUMBER: 2001:97624 USPATFULL
TITLE: Stabilized nucleic acid compositions and methods of preparation and use thereof
INVENTOR(S): Chen, Xian, San Diego, CA, United States
Ma, Chenglie, San Diego, CA, United States
D'Andrea, Mark J., Carlsbad, CA, United States
PATENT ASSIGNEE(S): Selective Genetics, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6251599	B1	20010626
APPLICATION INFO.:	US 1998-187727		19981106 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Houtteman, Scott W.
LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group PLLC
NUMBER OF CLAIMS: 82
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 2084
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Preparations of nucleic acid condensates and compositions containing such condensates are provided. The nucleic acid condensates are in the form of small particles that are stable when subjected to destabilizing conditions such as lyophilizing, freeze-thawing, and prolonged liquid storage. These compositions may be used to deliver nucleic acid to cells.

L9 ANSWER 40 OF 70 USPATFULL
ACCESSION NUMBER: 2001:55991 USPATFULL
TITLE: Inhibitors or bone reabsorption and antagonists of vitronectin receptors
INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of
Knolle, Jochen, Kriftel, Germany, Federal Republic of
Stilz, Hans Ulrich, Frankfurt, Germany, Federal Republic of
Carniato, Denis, Marcoussis, France
Gourvest, Jean-Francois, Claye Souilly, France
Gadek, Tom, Oakland, CA, United States
McDowell, Robert, San Francisco, CA, United States
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany,
Federal Republic of (non-U.S. corporation)
Genetech, Inc., San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6218415	B1	20010417
APPLICATION INFO.:	US 1997-821253		19970320 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19610919	19960320
	DE 1996-19626701	19960703
	DE 1996-19635522	19960902

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Higel, Floyd D.
ASSISTANT EXAMINER: Sackey, Ebenezer
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 3290
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors

The present invention relates to 5-membered ring heterocycles of the formula I, ##STR1##

in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation and to their use as medicaments.

The novel compounds are used as vitronectin receptor antagonists and as inhibitors of bone reabsorption.

L9 ANSWER 41 OF 70 USPATFULL
ACCESSION NUMBER: 2001:55963 USPATFULL
TITLE: Vitronectin receptor anatagonists, their preparation and their use
INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of
Stilz, Hans Ulrich, Frankfurt, Germany, Federal Republic of
Peyman, Anuschirwan, Kelkheim, Germany, Federal Republic of
Scheunemann, Karlheinz, Liederbach, Germany, Federal Republic of
Ruxer, Jean-Marie, Issy les Moulineaux, France
Carniato, Denis, Marcoussis, France
Lefrancois, Jean-Michel, Livry Gargan, France
Gadek, Thomas Richard, Oakland, CA, United States
McDowell, Robert, San Francisco, CA, United States
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt am Main, Germany,
Federal Republic of (non-U.S. corporation)
Genetech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6218387	B1	20010417
APPLICATION INFO.:	US 1999-412314		19991005 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-995522, filed on 22 Dec 1997, now patented, Pat. No. US 5990145		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19653646	19961220

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
ASSISTANT EXAMINER: Liu, Hoang
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 2356
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of the formula I,

A--B--D--E--P--G (I)

in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 42 OF 70 USPATFULL
ACCESSION NUMBER: 2001:52058 USPATFULL
TITLE: Integrin inhibitor prodrugs
INVENTOR(S): Jadhav, Prabhakar K., Wilmington, DE, United States
Batt, Douglas G., Wilmington, DE, United States
Hussain, Munir A., Wilmington, DE, United States
Pitts, William J., Newark, DE, United States
Repta, Arnold J., Wilmington, DE, United States
PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6214834	B1	20010410
APPLICATION INFO.:	US 1998-49305		19980327 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-41759P	19970328 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Rao, Deepak R.
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
LINE COUNT: 6833
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel heterocycles which are useful as antagonists of the .alpha..sub.v.beta..sub.3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, to iontophoretic delivery of such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

L9 ANSWER 43 OF 70 USPATFULL
ACCESSION NUMBER: 2001:44221 USPATFULL
TITLE: Vitronectin receptor antagonists, their preparation and use
INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of
Stilz, Hans Ulrich, Frankfurt, Germany, Federal Republic of
Peyman, Anuschirwan, Kelkheim, Germany, Federal Republic of
Knolle, Jochen, Kriftel, Germany, Federal Republic of
Ruxer, Jean-Marie, Issy les Moulineaux, France
Carniato, Denis, Marcoussis, France
LePrancois, Jean-Michel, Livry Gargan, France
Gadek, Thomas Richard, Oakland, CA, United States
McDowell, Robert, San Francisco, CA, United States
PATENT ASSIGNEE(S): Hoechst Atkiengesellschaft, Frankfurt, am Main, Germany, Federal Republic of (non-U.S. corporation)
Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6207663	B1	20010327
APPLICATION INFO.:	US 1999-412331		19991005 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-995521, filed on 22 Dec 1997, now patented, Pat. No. US 6011045		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19653647	19961220

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 3388
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Vitronectin receptor antagonists, their preparation and their use

The present invention relates to compounds of the formula I

A--B--D--E--P--G (I)

in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 44 OF 70 USPATFULL
ACCESSION NUMBER: 2001:19695 USPATFULL
TITLE: Iontophoretic delivery of integrin inhibitors
INVENTOR(S): Hussain, Munir A., Wilmington, DE, United States
Repta, Arnold J., Greenville, DE, United States
PATENT ASSIGNEE(S): DuPont Pharmaceuticals Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6185453	B1	20010206
APPLICATION INFO.:	US 1997-877829		19970618 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-20277P	19960619 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Weddington, Kevin E.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 3193
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel methods and devices for iontophoretically administering therapeutic doses of integrin receptor antagonists in a controlled manner through the skin. Such integrin receptor antagonists include but are not limited to antagonists of the IIb/IIIa and .alpha..sub.v.beta..sub.3 integrins and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices comprising integrin inhibitors. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

L9 ANSWER 45 OF 70 USPATFULL
ACCESSION NUMBER: 2001:4929 USPATFULL
TITLE: Chiral-.beta.-amino acid compounds and derivatives thereof
INVENTOR(S): Malecha, James W., Libertyville, IL, United States
Fraher, Thomas P., Chicago, IL, United States
PATENT ASSIGNEE(S): G.D. Searle & Co., Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6172256	B1	20010109
APPLICATION INFO.:	US 1999-261647		19990303 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-34270, filed on 4 Mar 1998, now abandoned
DOCUMENT TYPE: Patent
FILE SEGMENT: Granted
PRIMARY EXAMINER: Geist, Gary
ASSISTANT EXAMINER: Khare, D
LEGAL REPRESENTATIVE: Kovacevic, Cynthia S.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 1970
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a method for the preparation of a chiral .beta.-amino ester of the formula ##STR1##

wherein R is lower alkyl; and X and Y are the same or different Cl, Br or I.

L9 ANSWER 46 OF 70 USPATFULL
ACCESSION NUMBER: 2000:168146 USPATFULL
TITLE: Anti-human .**alpha**..**sub**.v .**beta**..**sub**.3 and .alpha..sub.v .beta..sub.5 antibodies
INVENTOR(S): Jonak, Zdenka Ludmila, SmithKline Beecham Corporation Corporate Intellectual Property-UW2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939
Taylor, Alexander, SmithKline Beecham Corporation Corporate Intellectual Property-UW2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939
Trulli, Stephen H, SmithKline Beecham Corporation Corporate Intellectual Property-UW2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939
Johanson, Kyung O, SmithKline Beecham Corporation Corporate Intellectual Property-UW2220 P.O. Box 1539, King of Prussia, PA, United States 19406-0939

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6160099		20001212
APPLICATION INFO.:	US 1998-199149		19981124 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Huff, Sheela
ASSISTANT EXAMINER: Helms, Larry R.
LEGAL REPRESENTATIVE: Baumeister, Kirk, King, William T.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 2245
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to a human .alpha..sub.v subunit-containing heterodimeric integrin receptors and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of disorders mediated by such receptors, such as cancer, in human patients.

L9 ANSWER 47 OF 70 USPATFULL
ACCESSION NUMBER: 2000:164081 USPATFULL
TITLE: Tissue factor methods and compositions for coagulation and tumor treatment
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
King, Steven W., Foothill Ranch, CA, United States
Gao, Boning, Dallas, TX, United States
PATENT ASSIGNEE(S): Board Of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6156321		20001205
APPLICATION INFO.:	US 1998-9822		19980120 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-42427P	19970327 (60)
	US 1997-36205P	19970127 (60)
	US 1997-35920P	19970122 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Williams, Morgan and Amerson
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1,3
NUMBER OF DRAWINGS: 25 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 7500
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, **targeted** immunotoxins, **targeted** coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.

L9 ANSWER 48 OF 70 USPATFULL
ACCESSION NUMBER: 2000:137819 USPATFULL
TITLE: Combined tissue factor and chemotherapeutic methods and
compositions for coagulation and tumor treatment
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
King, Steven W., Foothill Ranch, CA, United States
Gao, Boning, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6132729		20001017
APPLICATION INFO.:	US 1998-9217		19980120 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-42427P	19970327 (60)
	US 1997-36205P	19970127 (60)
	US 1997-35920P	19970122 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Williams, Morgan & Amerson
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 25 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 7498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulation-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, **targeted** immunotoxins, **targeted** coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVII activators.

L9 ANSWER 49 OF 70 USPATFULL
ACCESSION NUMBER: 2000:102455 USPATFULL
TITLE: Amino benzenepropanoic acid compounds and derivatives thereof
INVENTOR(S): Collins, Joe T., Ballwin, MO, United States
Devadas, Balekudru, Chesterfield, MO, United States
Lu, Hwang-fun, Ballwin, MO, United States
Malecha, James W., Libertyville, IL, United States
Miyashiro, Julie Marion, Skokie, IL, United States
Nagarajan, Srinivasan, Chesterfield, MO, United States
Rico, Joseph Gerace, Ballwin, MO, United States
Rogers, Thomas E., Ballwin, MO, United States
PATENT ASSIGNEE(S): G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6100423		20000808
APPLICATION INFO.:	US 1999-261822		19990303 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-34758, filed on 4 Mar 1998 which is a continuation-in-part of Ser. No. US 1996-713555, filed on 27 Aug 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-3277P	19950830 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jose' G.
ASSISTANT EXAMINER: Qazi, Sabiha N.
LEGAL REPRESENTATIVE: Kovacevic, Cynthia S.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 1693
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds of the formula ##STR1## where R.sup.1 is BOC or H, R is H or lower alkyl; X and Y are the same or different halo atoms selected from the group consisting of Cl, Br or I and pharmaceutically acceptable salts and isomers thereof.

L9 ANSWER 50 OF 70 USPATFULL
ACCESSION NUMBER: 2000:94698 USPATFULL
TITLE: Methods and compositions for the specific coagulation of vasculature
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Edgington, Thomas S., La Jolla, CA, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6093399		20000725
APPLICATION INFO.:	US 1995-482369		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-273567, filed on 11 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-205330, filed on 2 Mar 1994 which is a continuation-in-part of Ser. No. US 1992-846349, filed on 5 Mar 1992, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Arnold, White & Durkee, P.C.
NUMBER OF CLAIMS: 103
EXEMPLARY CLAIM: 1,102
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 7405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.

L9 ANSWER 51 OF 70 USPATFULL
ACCESSION NUMBER: 2000:67747 USPATFULL
TITLE: Vitronectin receptor antagonists
INVENTOR(S): Miller, William H., Schwenksville, PA, United States
Bondinell, William E., Wayne, PA, United States
Ku, Thomas Wen Fu, Dresher, PA, United States
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6069158		20000530
	WO 9830542		19980716
APPLICATION INFO.:	US 1999-331914		19990629 (9)
	WO 1998-US490		19980108
			19990629 PCT 371 date
			19990629 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-34026P	19970108 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Davis, Zinna Northington
LEGAL REPRESENTATIVE: McCarthy, Mary E., Venetianer, Stephne, Kinzig, Charles M.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 1729
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to certain tricyclic compounds that are integrin receptor antagonists.

L9 ANSWER 52 OF 70 USPATFULL
ACCESSION NUMBER: 2000:64874 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Duggan, Mark E., Schwenksville, PA, United States
Meissner, Robert S., Schwenksville, PA, United States
Perkins, James J., Churchville, PA, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6066648		20000523
APPLICATION INFO.:	US 1998-212123		19981215 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69910P	19971217 (60)
	US 1998-83251P	19980427 (60)
	US 1998-92588P	19980713 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Keating, Dominic
LEGAL REPRESENTATIVE: Durette, Philippe L., Winokur, Melvin, Sabatelli, Anthony D.
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
LINE COUNT: 4780
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors .alpha..nu..beta.3 and/or .alpha..nu..beta.5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

L9 ANSWER 53 OF 70 USPATFULL
ACCESSION NUMBER: 2000:53742 USPATFULL
TITLE: Method of treatment of arterial and venous thromboembolic disorders
INVENTOR(S): Mousa, Shaker Ahmed, Lincoln University, PA, United States
PATENT ASSIGNEE(S): Dupont Pharmaceuticals, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6056958		20000502
APPLICATION INFO.:	US 1997-901344		19970728 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-353419, filed on 9 Dec 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: MacMillan, Keith B.
ASSISTANT EXAMINER: Wessendorf, T. D.
LEGAL REPRESENTATIVE: Vance, David H., Rubin, Kenneth B.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 2186
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to a method of prevention and/or treatment of thrombosis in a mammal without significantly altering bleeding time or coagulation. This invention further relates to methods of using selective inhibitors of the binding of vitronectin to the .alpha..sub.v .beta..sub.3 receptor, alone or in combination with other therapeutic agents, for the inhibition of thrombus formation and/or the treatment of thromboembolic disorders.

L9 ANSWER 54 OF 70 USPATFULL
ACCESSION NUMBER: 2000:50562 USPATFULL
TITLE: Receptor-mediated gene delivery using bacteriophage vectors
INVENTOR(S): Larocca, David, Encinitas, CA, United States
Baird, Andrew, San Diego, CA, United States
Johnson, Wendy, Encinitas, CA, United States
PATENT ASSIGNEE(S): Selective Genetics, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6054312		20000425
APPLICATION INFO.:	US 1997-920396		19970829 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Brusca, John S.
LEGAL REPRESENTATIVE: Seed Intellectual Property Law Group
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 2350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Filamentous phage particles displaying a **ligand** on their surface are used to deliver a therapeutic gene to a cell. The **ligand** is a fusion protein with a phage capsid protein, covalently conjugated to phage particles, or complexed with modified phage particles.

L9 ANSWER 55 OF 70 USPATFULL
ACCESSION NUMBER: 2000:31029 USPATFULL
TITLE: Kits and methods for the specific coagulation of vasculature
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Edgington, Thomas S., La Jolla, CA, United States
PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6036955		20000314
APPLICATION INFO.:	US 1995-479727		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-273567, filed on 11 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-205330, filed on 2 Mar 1994 which is a continuation-in-part of Ser. No. US 1992-846349, filed on 5 Mar 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Arnold, White & Durkee, L.L.P.
NUMBER OF CLAIMS: 102
EXEMPLARY CLAIM: 1,50
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 7366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.

L9 ANSWER 56 OF 70 USPATFULL
ACCESSION NUMBER: 2000:21206 USPATFULL
TITLE: Structurally determined metallo-constructs and applications
INVENTOR(S): Sharma, Shubh D., Albuquerque, NM, United States
PATENT ASSIGNEE(S): RhoMed Incorporated, Edison, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6027711		20000222
APPLICATION INFO.:	US 1996-660697		19960605 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-476652, filed on 7 Jun 1995, now patented, Pat. No. US 5891418, issued on 6 Apr 1999
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jose G.
ASSISTANT EXAMINER: Jones, Dameron
LEGAL REPRESENTATIVE: Slusher, Stephen A., Todaro, John C., Peacock, Deborah A.
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 4915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A metallo-construct, which may be a **peptide**, is provided for use as a biological, therapeutic, diagnostic imaging, or radiotherapeutic agent, and for use in library or combinatorial chemistry methods. The construct has a conformationally constrained global secondary structure obtained upon complexing with a **metal** ion. The **peptide** constructs are of the general formula:

R.sub.1 --X--R.sub.2

where X is a plurality of amino acids and includes a complexing backbone for complexing **metal** ions, so that substantially all of the valences of the **metal** ion are satisfied upon complexation of the **metal** ion with X, resulting in a specific regional secondary structure forming a part of the global secondary structure; and where R.sub.1 and R.sub.2 each include from 0 to about 20 amino acids, the amino acids being selected so that upon complexing the **metal** ion with X at least a portion of either R.sub.1 or R.sub.2 or both have a structure forming the balance of the conformationally constrained global secondary structure. All or a portion of the global secondary structure, which may be sychnologic or rhegnylogic, may form a **ligand** or mimic a known biological-function domain. The construct has substantially higher affinity for its **target** upon labeling with a **metal** ion.

L9 ANSWER 57 OF 70 USPATFULL
ACCESSION NUMBER: 2000:4943 USPATFULL
TITLE: Integrin-linked kinase and its uses
INVENTOR(S): Dedhar, Shoukat, Vancouver, Canada
Hannigan, Greg, Ontario, Canada
PATENT ASSIGNEE(S): Sunnybrook Health Sciences Center, Ontario, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6013782		20000111
APPLICATION INFO.:	US 1997-955841		19971021 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-752345, filed on 19 Nov 1996, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-9074P	19951221 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Campell, Bruce R.
ASSISTANT EXAMINER: Chen, Shin-Lin
LEGAL REPRESENTATIVE: Sherwood, PamelaBozicevic, Field & Francis
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 2569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for isolating ILK genes are provided. The ILK nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.

L9 ANSWER 58 OF 70 USPATFULL
ACCESSION NUMBER: 2000:4813 USPATFULL
TITLE: Meta-azacyclic amino benzoic acid compounds and derivatives thereof
INVENTOR(S): Rogers, Thomas E., Ballwin, MO, United States
Ruminski, Peter G., Dardenne Prairie, MO, United States
PATENT ASSIGNEE(S): G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6013651		20000111
APPLICATION INFO.:	US 1998-34758		19980304 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-713555, filed on 27 Aug 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-3277P	19950830 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jose' G.
ASSISTANT EXAMINER: Qazi, Sabiha N.
LEGAL REPRESENTATIVE: Kovacevic, Cynthia S.
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
LINE COUNT: 2002
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to compounds of the formula ##STR1## and pharmaceutically acceptable salts and isomers thereof.

L9 ANSWER 59 OF 70 USPATFULL
ACCESSION NUMBER: 2000:1888 USPATFULL
TITLE: Vitronectin receptor antagonists, their preparation and their use
INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of
Stilz, Hans Ulrich, Frankfurt, Germany, Federal Republic of
Peyman, Anuschirwan, Kelkheim, Germany, Federal Republic of
Knolle, Jochen, Kriftel, Germany, Federal Republic of
Ruxer, Jean-Marie, Issy les Moulineaux, France
Carniato, Denis, Marcoussis, France
Lefrancois, Jean-Michel, Livry Gargan, France
Gadek, Thomas Richard, Oakland, CA, United States
McDowell, Robert, San Francisco, CA, United States
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfur am Main, United States (non-U.S. corporation)
Genentech, Inc., San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6011045		20000104
APPLICATION INFO.:	US 1997-995521		19971222 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19653647	19961220

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 3262
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of the formula I

A--B--D--E--F--G (I)

in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 60 OF 70 USPATFULL
ACCESSION NUMBER: 1999:167157 USPATFULL
TITLE: Imino compounds, process for their preparation and their use as victronectin antagonists
INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of
Knolle, Jochen, Kriftel, Germany, Federal Republic of
Stilz, Hans Ulrich, Frankfurt, Germany, Federal Republic of
Gourvest, Jean-Francois, Claye Souilly, France
Carniato, Denis, Clamart, France
Gadek, Thomas Richard, Oakland, CA, United States
McDowell, Robert, San Francisco, CA, United States
Pitti, Robert Maurice, El Cerrito, CA, United States
Bodary, Sarah Catherine, San Bruno, CA, United States
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6005117		19991221
APPLICATION INFO.:	US 1997-899887		19970724 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19629817	19960724

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Higel, Floyd D.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1,7
LINE COUNT: 1629
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There are described imino derivatives of formula (I)

R.sup.1 --Y--A--B--D--E--F--G (I)

their preparation and their use as medicaments. The compounds according to the invention may be used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 61 OF 70 USPATFULL
ACCESSION NUMBER: 1999:166596 USPATFULL
TITLE: Methods for the specific coagulation of vasculature
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Edgington, Thomas S., La Jolla, CA, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6004555		19991221
APPLICATION INFO.:	US 1995-487427		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-273567, filed on 11 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-205330, filed on 2 Mar 1994 which is a continuation-in-part of Ser. No. US 1992-846349, filed on 5 Mar 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Eyler, Yvonne
LEGAL REPRESENTATIVE: Arnold, White & Durkee, P.C.
NUMBER OF CLAIMS: 87
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 7393
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.

L9 ANSWER 62 OF 70 USPATFULL
ACCESSION NUMBER: 1999:163477 USPATFULL
TITLE: Integrin-linked kinase and its use
INVENTOR(S): Dedhar, Shoukat, Vancouver, Canada
Hannigan, Greg, Ontario, Canada
PATENT ASSIGNEE(S): Sunnybrook Health Science Centre, Ontario, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6001622		19991214
APPLICATION INFO.:	US 1998-35706		19980305 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-955841, filed on 21 Oct 1997 which is a continuation-in-part of Ser. No. US 1996-752345, filed on 19 Nov 1996

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-9074P	19951221 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Achutamurthy, Ponnathapu
LEGAL REPRESENTATIVE: Bozicevic, Field & Francis LLP, Sherwood, Pamela
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 23 Drawing Page(s)
LINE COUNT: 3148
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for isolating ILK genes are provided. The ILK nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as identification of cell type based on expression, and the like.

L9 ANSWER 63 OF 70 USPATFULL
ACCESSION NUMBER: 1999:151248 USPATFULL
TITLE: Vitronectin receptor antagonists, their preparation and their use
INVENTOR(S): Wehner, Volkmar, Sandberg, Germany, Federal Republic of
Stilz, Hans Ulrich, Frankfurt, Germany, Federal Republic of
Peyman, Anuschirwan, Kelkheim, Germany, Federal Republic of
Scheunemann, Karlheinz, Liederbach, Germany, Federal Republic of
Ruxer, Jean-Marie, Issy les Moulineaux, France
Carniato, Denis, Marcoussis, France
Lefrancois, Jean-Michel, Livry Gargan, France
Gadek, Thomas Richard, Oakland, CA, United States
McDowell, Robert, San Francisco, CA, United States
PATENT ASSIGNEE(S): Hoechst Aktiengesellschaft, Frankfurt Am Main, Germany, Federal Republic of (non-U.S. corporation)
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5990145		19991123
APPLICATION INFO.:	US 1997-995522		19971222 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19653645	19961220

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 2238
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to compounds of the formula I,

A--B--D--E--F--G (I)

in which A, B, D, E, F and G have the meanings given in the patent claims, to their preparation and to their use as medicaments. The compounds of the invention are used as vitronectin receptor antagonists and as inhibitors of bone resorption.

L9 ANSWER 64 OF 70 USPATFULL
ACCESSION NUMBER: 1999:120389 USPATFULL
TITLE: Iontophoretic delivery of cell adhesion inhibitors
INVENTOR(S): Sage, Burton H., 7001 Jeffrey Dr., Raleigh, NC, United States 27603
Bock, Carl Randolph, 1334 Welcome Cir., Durham, NC, United States 17705
Green, Philip G., 17G Carlyle Towers South 100 Winston Dr., Cliffside Park, NJ, United States 07010
Hussain, Munir A., 619 Andover Rd., Wilmington, DE, United States 19803
Repta, Arnold J., 920 Fairborne Ave., Greenville, DE, United States 19807

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5961483		19991005
APPLICATION INFO.:	US 1997-878493		19970618 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-724105, filed on 30 Sep 1996, now abandoned And Ser. No. US 1996-724106, filed on 30 Sep 1996, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Brouillette, D. Gabrielle
LEGAL REPRESENTATIVE: Hoffmann & Baron, LLP
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 6393
AB This invention relates to novel methods and devices for iontophoretically administering therapeutic doses of cell adhesion receptor antagonists in a controlled manner through the skin. Such antagonist compounds include but are not limited to antagonists of the IIb/IIIa and .alpha..sub.v .beta..sub.3 integrins and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices comprising cell adhesion receptor antagonists. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

L9 ANSWER 65 OF 70 USPATFULL
ACCESSION NUMBER: 1999:92317 USPATFULL
TITLE: Iontophoretic delivery of cell adhesion inhibitors
INVENTOR(S): Sage, Burton H., Raleigh, NC, United States
Bock, Carl Randolph, Durham, NC, United States
Green, Philip G., Cliffside Park, NJ, United States
PATENT ASSIGNEE(S): Becton Dickinson Research Center, Research Triangle Park, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5935598		19990810
APPLICATION INFO.:	US 1997-877602		19970618 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-724105, filed on 30 Jun 1996, now abandoned And a continuation-in-part of Ser. No. US 1996-724106, filed on 30 Jun 1996, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dees, Jose' G.
ASSISTANT EXAMINER: Shelborne, Kathryne E.
LEGAL REPRESENTATIVE: Hoffmann & Baron, LLP
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4525

AB This invention relates to novel methods and devices for iontophoretically administering therapeutic doses of cell adhesion receptor antagonists in a controlled manner through the skin. Such antagonist compounds include but are not limited to antagonists of the IIb/IIIa and .alpha..sub.v .beta..sub.3 inter and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices comprising cell adhesion receptor antagonists. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

L9 ANSWER 66 OF 70 USPATFULL
ACCESSION NUMBER: 1999:27746 USPATFULL
TITLE: Tissue factor compositions and ligands for the specific coagulation of vasculature
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Edgington, Thomas S., La Jolla, CA, United States
PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)
Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5877289		19990302
APPLICATION INFO.:	US 1995-479733		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-273567, filed on 11 Jul 1994 which is a continuation-in-part of Ser. No. US 1994-205330, filed on 2 Mar 1994, now patented, Pat. No. US 5855866 which is a continuation-in-part of Ser. No. US 1992-846349, filed on 5 Mar 1992
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Bansal, Geetha P.
LEGAL REPRESENTATIVE: Arnold White & Durkee L.L.P.
NUMBER OF CLAIMS: 100
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 7148
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.

L9 ANSWER 67 OF 70 USPATFULL
ACCESSION NUMBER: 1998:82717 USPATFULL
TITLE: Fivemer cyclic peptide inhibitors of diseases involving .alpha..sub.v .beta..sub.3
INVENTOR(S): Palladino, Michael A., Olivenhain, CA, United States
Lee, Bruce A., San Diego, CA, United States
Huse, William D., San Diego, CA, United States
Varner, Judith A., Encinitas, CA, United States
PATENT ASSIGNEE(S): IXSYS, Incorporated, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5780426		19980714
APPLICATION INFO.:	US 1995-482107		19950607 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Walsh, Stephen
ASSISTANT EXAMINER: Brown, Karen E.
LEGAL REPRESENTATIVE: Needle & Rosenberg, P.C.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 1944
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes non-RGD cyclic peptides that inhibit the function of the integrin receptor, .alpha..sub.v .beta..sub.3. The inventive peptides are between five to about thirty amino acids in length and include the sequence (SEQ ID NO:8), Arg-Cys-Asp-Gly-X.sub.i where X.sub.i is any amino acid, and a five-membered cyclic portion. These non-RGD peptides display surprisingly potent antagonist activity despite the lack of the consensus binding sequence Arg-Gly-Asp, and present opportunities for selective targeting to the .alpha..sub.v .beta..sub.3 receptor. Pharmaceutical compositions and methods of use are also disclosed. The therapeutic uses for the inventive peptides include treating diseases involving .alpha..sub.v .beta..sub.3 receptors such as cancer, osteoporosis, restenosis, and angiogenic-based diseases.

L9 ANSWER 68 OF 70 USPATFULL
ACCESSION NUMBER: 1998:75789 USPATFULL
TITLE: Meta-substituted phenylene derivatives
INVENTOR(S): Chandrakumar, Nizal, Vernon Hills, IL, United States
Chen, Barbara B., Glenview, IL, United States
Chen, Helen Y., Livingston, NJ, United States
Clare, Michael, Sokie, IL, United States
Gasiecki, Alan F., Vernon Hills, IL, United States
Haack, Richard A., Chicago, IL, United States
Malecha, James W., Libertyville, IL, United States
Ruminski, Peter G., Ballwin, MO, United States
Russell, Mark A., Gurnee, IL, United States
PATENT ASSIGNEE(S): G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5773646		19980630
APPLICATION INFO.:	US 1997-825086		19970327 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-14464P	19960329 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Geist, Gary
ASSISTANT EXAMINER: Davis, Brian J.
LEGAL REPRESENTATIVE: Kovacevic, Cynthia S., Williams, Roger A.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 4574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a class of compounds represented by the Formula I ##STR1## or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .alpha..sub.v .beta..sub.3 integrin.

L9 ANSWER 69 OF 70 USPATFULL
ACCESSION NUMBER: 1998:68993 USPATFULL
TITLE: Sevenmer cyclic **peptide** inhibitors of diseases involving .**alpha**..**sub**. **v** .**beta**..**sub**.**3**
INVENTOR(S): Palladino, Michael A., Olivenhain, CA, United States
Lee, Bruce A., San Diego, CA, United States
Huse, William D., Del Mar, CA, United States
Varner, Judith A., Encinitas, CA, United States
PATENT ASSIGNEE(S): IXSYS Incorporated, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5767071		19980616
APPLICATION INFO.:	US 1995-482106		19950607 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Borin, Michael
LEGAL REPRESENTATIVE: Needle & Rosenberg, P.C.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 1997
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention includes non-RGD, nine amino acid cyclic **peptides** that inhibit the function of the integrin receptor, .**alpha**..**sub**.**v** .**beta**..**sub**.**3**. These **peptides** display surprisingly potent antagonist activity despite the lack of the consensus binding sequence Arg-Gly-Asp, and present opportunities for selective **targeting** to the .**alpha**..**sub**.**v** .**beta**..**sub**.**3** receptor. Pharmaceutical compositions and methods of use are also disclosed. The therapeutic uses for the inventive **peptides** include treating diseases involving .**alpha**..**sub**.**v** .**beta**..**sub**.**3** receptors such as osteoporosis, restenosis, and angiogenic-based diseases, including cancer, arthritis, and diabetic retinopathy.

L9 ANSWER 70 OF 70 USPATFULL
ACCESSION NUMBER: 1998:61644 USPATFULL
TITLE: Spirocycle integrin inhibitors
INVENTOR(S): Jadhav, Prabhakar Kondaji, Wilmington, DE, United States
Smallheer, Joanne Marie, Landenberg, PA, United States
PATENT ASSIGNEE(S): The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5760029		19980602
APPLICATION INFO.:	US 1997-816580		19970313 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-13539P	19960315 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Grumbling, Matthew V.
LEGAL REPRESENTATIVE: Ferguson, Blair Q.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 5723
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel heterocycles, including (S)-2-phenylsulfonylamino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino] propionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.